<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171170</url>
  </required_header>
  <id_info>
    <org_study_id>NVALT12</org_study_id>
    <nct_id>NCT01171170</nct_id>
  </id_info>
  <brief_title>Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer</brief_title>
  <acronym>NVALT12</acronym>
  <official_title>A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Society of Physicians for Pulmonology and Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dutch Society of Physicians for Pulmonology and Tuberculosis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effects of adding nitroglycerin (NTG) patches, delivery
      25 mg NTG per 24 h, to the standard first line treatment of metastatic non-squamous non-small
      cell lung cancer (NSCLC), i.e. 4 cycles of carboplatin-paclitaxel-bevacizumab, followed by
      bevacizumab alone until disease progression. Tumor hypoxia is a common phenomenon in lung
      cancer; it is a known poor prognostic marker, related to treatment resistance. Pre-clinical
      studies have shown that nitric oxide (NO) donating drugs may decrease hypoxia related drug
      resistance. NTG is a NO donating drug. NTG increases tumor blood flow and thereby augments
      antitumor drug delivery to the tumor.

      A randomized phase II has shown an increase in the response rate from 42% to 72%, when NTG
      patches (25 mg/day, day -2 to +3) were added to vinorelbine/cisplatin in patients with
      advanced NSCLC. In addition, the time to progression increased from 185 to 327 days.

      The hypothesis of the present study is that adding NTG transdermal patches to bevacizumab
      containing chemotherapy improves progression free survival, response rate and overall
      survival in patients with metastatic non-squamous NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment for non-small cell lung cancer (NSCLC) consists of platinum-containing
      chemotherapy. It has been shown that the addition of bevacizumab to standard chemotherapy
      improves progression-free survival (PFS) and overall survival (OS) in patients with
      non-squamous NSCLC. There is a need for improved PFS and OS and response rates to
      chemotherapy are only 25-35%.

      Tumor hypoxia is a common phenomenon in lung cancer; it is a known poor prognostic marker,
      related to treatment resistance. Hypoxia Inducible Factor (HIF) -1α is the major factor
      regulating the response to hypoxia.

      HIF directly activates vascular endothelial growth factor (VEGF) and VEGF-receptor.
      Bevacizumab interacts with this pathway by blocking VEGF.

      Pre-clinical studies have shown that nitric oxide (NO) donating drugs may decrease hypoxia
      related drug resistance. Nitroglycerin (NTG) is a NO donating drug. NTG increases tumor blood
      flow and thereby augments antitumor drug delivery to the tumor and inhibits HIF-1α.

      Interestingly, it has recently been shown in mouse models that the addition of HIF-1α
      inhibitors to bevacizumab significantly inhibits tumor growth by inducing apoptosis.

      A randomized phase II has shown an increase in the response rate from 42% to 72%, when NTG
      patches (25 mg/day, day -2 to +3) were added to vinorelbine/cisplatin in patients with
      advanced NSCLC. In addition, the time to progression increased from 185 to 327 days.

      The hypothesis of the present study is that adding NTG transdermal patches to bevacizumab
      containing chemotherapy improves PFS, response rate and OS in patients with metastatic
      non-squamous NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>every 6 weeks during chemotherapy</time_frame>
    <description>Imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>every 6 weeks during chemotherapy</time_frame>
    <description>Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>every 6 weeks during chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>every 6 weeks during chemotherapy</time_frame>
    <description>Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>every 3 weeks during chemotherapy</time_frame>
    <description>adverse events, hematology, chemistry, physial examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prediction of early response</measure>
    <time_frame>after 3 weeks</time_frame>
    <description>FDG PET scan (exploratory objective)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decreased hypoxia</measure>
    <time_frame>after 6 weeks</time_frame>
    <description>FAZA scan (exploratory objective)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>carboplatin-paclitaxel-bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paclitaxel 200 mg/m2 d1 - carboplatin area under the curve (AUC) 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment plus nitroglycerin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin paclitaxel bevacizumab</intervention_name>
    <description>paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression</description>
    <arm_group_label>carboplatin-paclitaxel-bevacizumab</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment plus nitroglycerin</intervention_name>
    <description>paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle</description>
    <arm_group_label>standard treatment plus nitroglycerin</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically proven stage IV non-squamous NSCLC (according to IASLC
             staging 7.0)

          -  No prior chemotherapy or therapy with systemic anti-tumor therapy (e.g., monoclonal
             antibody therapy) or prior exposure to agents directed at the HER axis (e.g. epidermal
             growth factor receptor tyrosine kinase inhibitors (EGFR TKI), Herceptin). Prior
             surgery and/or localized palliative irradiation is permitted provided that the
             irradiated lesion is not the only measurable lesion. Prior adjuvant chemotherapy &gt; 1
             year ago and prior treatment with an EGFR-TKI for patients with an activating EGFR
             mutation is allowed.

          -  Age ≥ 18 years.

          -  ECOG Performance Status of 0 - 2.

          -  Life expectancy of at least 12 weeks.

          -  Subjects with at least one uni-dimensional(for RECIST) measurable lesion.

          -  Adequate bone marrow, liver and renal function.

          -  Adequate non-hormonal contraception for females of childbearing potential during the
             study and in the 6 months thereafter.

          -  Adequate contraception for male participants (or their partners) during the study and
             in the 6 months thereafter.

        Exclusion Criteria:

          -  Clinically significant (i.e. active) cardiovascular disease: congestive heart failure
             &gt;NYHA class 2; CVA or myocardial infarction &lt; 6 months prior to study entry;
             uncontrolled hypertension (blood pressure systolic &gt; 150 mmHg and/or diastolic &gt; 100
             mmHg).

          -  Symptomatic hypotension.

          -  History of hemoptysis at least grade 2 (bright red blood of at least 2,5 ml in the
             last 3 months)

          -  Evidence of tumor invading major blood vessels on imaging (i.e. superior vena cava or
             pulmonary artery).

          -  History of HIV infection or chronic hepatitis B or C.

          -  Active clinically serious infection

          -  Symptomatic metastatic brain or meningeal tumors. Patients with brain metastasis may
             be included the patient is treated with brain radiotherapy and asymptomatic.

          -  History of organ allograft.

          -  Patients with evidence or history of bleeding diathesis.

          -  Non-healing wound or ulcer.

          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
             within 6 months of enrolment

          -  Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study
             entry

          -  Radiotherapy within 4 weeks of start of study drug. Palliative radiotherapy for bone
             lesions is allowed &gt; 14 days of start of chemotherapy. Major surgery within 4 weeks of
             start of study.

          -  Use of vasodilators (including 5-phosphodiesterase inhibitors, calcium antagonists or
             nitrates)

          -  Autologous bone marrow transplant or stem cell rescue within 4 months of study

          -  Investigational drug therapy outside of this trial during or within 4 weeks of study
             entry

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Marie C. Dingemans, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Marie C. Dingemans, MD PhD</last_name>
    <phone>+31 43 3875047</phone>
    <email>rsc@rsconsultancy.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond J. Schmidt, MD</last_name>
    <phone>+31 575 441001</phone>
    <email>rsc@rsconsultancy.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU medisch centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smit</last_name>
      <email>ef.smit@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Egbert F. Smit, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aerts</last_name>
      <email>jaerts@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>Joachim G. Aerts, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biesma</last_name>
      <email>b.biesma@jbz.nl</email>
    </contact>
    <investigator>
      <last_name>Bonne Biesma, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina-Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van den Borne</last_name>
      <email>ben.vd.borne@cze.nl</email>
    </contact>
    <investigator>
      <last_name>Ben E. van den Borne, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van Putten</last_name>
      <email>jwg.van.putten@mzh.nl</email>
    </contact>
    <investigator>
      <last_name>John W. van Putten, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie C. Dingemans, MD PhD</last_name>
      <email>a.dingemans@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie C. Dingemans, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Codrington</last_name>
      <email>h.codrington@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Henk E. Codrington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stigt</last_name>
      <email>j.a.stigt@isala.nl</email>
    </contact>
    <investigator>
      <last_name>Jos A. Stigt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.nvalt.nl</url>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <last_update_submitted>July 26, 2011</last_update_submitted>
  <last_update_submitted_qc>July 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Anne-Marie C. Dingemans, MD PhD</name_title>
    <organization>Maastricht UMC</organization>
  </responsible_party>
  <keyword>non small cell lung cancer</keyword>
  <keyword>stage IV</keyword>
  <keyword>nitroglycerin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

